Eribulin every two weeks vs standard schedule for advanced breast cancer
Part of Cancer clinical trials.
This trial compares a new every-two-week dosing schedule of the chemotherapy drug eribulin to the standard schedule in people with HER2-negative breast cancer that has returned or spread. The goal is to see if the biweekly regimen is safer or works better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have HER2-negative breast cancer that has come back or spread to other parts of the body
- You have received up to 3 previous chemotherapy treatments for advanced disease
- You have had previous treatment with anthracycline and paclitaxel types of chemotherapy
- You have at least one tumor that can be measured on a scan
- Your overall health is fairly good (able to do daily activities with little or no help)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs, eribulin and bevacizumab, for people with advanced HER2-negative breast cancer. It aims to see how well the treatment works and why it may or may not work.
This trial tests a new medicine called ESG401 for people with a common type of breast cancer (HR+/HER2-) that has spread and hasn't responded to at least one chemotherapy. The goal is to see if it works better than standard chemotherapy options.
This trial tests a new drug called SKB264 for people with a common type of breast cancer (HR+/HER2-) that has spread or come back and has not responded to at least one round of chemotherapy. It aims to see if this treatment can help shrink tumors or slow the disease.
This trial tests a chemotherapy drug called eribulin, alone or with other medicines, in people with advanced HER2-negative breast cancer that has already been treated with an antibody-drug conjugate (ADC). It aims to see if eribulin can help when standard ADC treatment has stopped working.
This trial tests a combination of two drugs—eribulin (a chemotherapy) and sintilimab (an immunotherapy that helps your immune system attack cancer)—as a first treatment for women with advanced HER2-negative breast cancer that cannot be removed by surgery.
This trial tests a combination of two cancer drugs (eribulin and anlotinib) for women whose breast cancer has spread and stopped responding to previous treatments, particularly antibody-drug conjugates. The study aims to see if this combination can help slow or shrink the cancer.
Hear when a new Breast Cancer Metastatic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.